RE: Glaxo Loses Bid to Toss Vectura Verdict Over Lung Inhalers19 Nov 2020 21:17
Great news
"As reported in March 2020, Vectura has estimated that damages, accumulated interest and ongoing royalties could amount to approximately $200m in total. The precise amounts to be received are dependent on the future US sales of the infringing products as well as sales for historical periods yet to be reported by GSK"
The law is an ass however, even after all this time:
"GSK has 30 days to file a petition for rehearing"